Trial Profile
A Phase II, Randomized, 4-Week, Double-Blind, Placebo-Controlled, Multiple-Dose Study, Designed to Determine the Safety, Tolerability, EEG Effects and Preliminary Efficacy of Fixed Oral Doses of 7.5 and 15 MG BID of Evenamide in Patients With Chronic Schizophrenia Who Are Symptomatic on Their Current Second-Generation Antipsychotic Medication
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 May 2021
Price :
$35
*
At a glance
- Drugs Evenamide (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Newron Pharmaceuticals
- 17 May 2021 Status changed from active, no longer recruiting to completed.
- 01 Apr 2021 According to a Newron Pharmaceuticals media release, this study was requested by the FDA to address questions which arose from a study of evenamide in rats, and central nervous system (CNS) events observed following high-dose administration of evenamide in dogs.
- 01 Apr 2021 Results presented in a Newron Pharmaceuticals media release.